{"id":"cj-12420-clarithromycin-amoxicillin","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Taste disturbance"},{"rate":null,"effect":"Allergic reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a triple-agent combination where amoxicillin inhibits bacterial cell wall synthesis by binding penicillin-binding proteins, clarithromycin inhibits bacterial protein synthesis by binding the 50S ribosomal subunit, and CJ-12420 (mechanism not fully disclosed in public literature) appears designed to enhance efficacy or overcome resistance. The combination targets Helicobacter pylori and other susceptible bacteria through complementary mechanisms.","oneSentence":"CJ-12420 is a novel compound combined with clarithromycin and amoxicillin to provide enhanced antimicrobial activity, likely through synergistic bacterial cell wall disruption and protein synthesis inhibition.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:06:08.143Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Helicobacter pylori infection (eradication therapy)"}]},"trialDetails":[{"nctId":"NCT03317223","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy and Safety of Triple Therapy With CJ-12420 in H. Pylori Positive Patients","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2017-10-17","conditions":"Helicobacter Pylori Infection","enrollment":350},{"nctId":"NCT03011996","phase":"PHASE1","title":"To Investigate PK and PD of CJ-12420, Clarithromycin, Amoxicillin After Multiple Dose Administration","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2016-05","conditions":"Drug Interaction, Pharmacokinetic, Pharmacodynamic","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lansoprazole/Clarithromycin/Amoxicillin"],"phase":"phase_3","status":"active","brandName":"CJ-12420/Clarithromycin/Amoxicillin","genericName":"CJ-12420/Clarithromycin/Amoxicillin","companyName":"HK inno.N Corporation","companyId":"hk-inno-n-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CJ-12420, a small molecule, is being investigated in combination with clarithromycin and amoxicillin (amoxicillin sodium) for its pharmacokinetic and pharmacodynamic effects, particularly in treating Helicobacter pylori infection. The study involves administering CJ-12420 at doses of 100mg and 50mg, along with clarithromycin 500mg, to evaluate their interaction and safety after multiple dose administration.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}